Document is current
Any future updates will be listed below
-
Authors
Chu, Jeffrey https://orcid.org/0009-0005-5306-3982
Shaia, Jacqueline K. https://orcid.org/0000-0001-7873-669X
Jeong, Hejin https://orcid.org/0009-0001-7903-0792
Singh, Rishi P.
Talcott, Katherine E. https://orcid.org/0000-0003-0458-4181
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (T32 EY024236)
Research to Prevent Blindness (P30EY025585(BA-A), P30EY025585(BA-A))
- License Information
-
More Information
Article History
Received: 7 May 2024
Revised: 19 February 2025
Accepted: 8 May 2025
First Online: 20 May 2025
Competing interests
: RPS reports personal fees from Genentech/Roche, Alcon, Novartis, Regeneron, Asclepix, Gyroscope, Bausch and Lomb, Apellis. KET reports personal fees from Genentech/Roche, research fees from Zeiss and Regenxbio. AR reports consulting fees from Alcon, Genentech, Apellis, Iveric Bio, and Zeiss, speaking fees from Apellis, Genentech, and Regeneron, and research fees from AGTC, Apellis, Genentech, and NGM Bio.
